Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices

Published: Friday, August 03, 2012
Last Updated: Friday, August 03, 2012
Bookmark and Share
Paragon Bioservices to perform process development for the contract manufacturing of recombinant proteins and antibodies.

CEVEC Pharmaceuticals and Paragon Bioservices, Inc. have announced a joint collaboration earlier whereby Paragon Bioservices would license and use CEVEC's know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

"We are very pleased to be working with Paragon Bioservices," said Wolfgang Kintzel, CEVEC's CEO. "Since they provide preclinical research and development services and protein production for many of the large pharmaceutical companies, we believe that our collaboration will inevitably benefit the research community at-large."

Paragon's CEO, Marco Chacón, PhD, agrees, "Even though our upstream developmental team has many years of experience in cell biology and bioprocess development, this is a highly competitive business. Everyone needs an edge to meet the outsourcing challenges of our clients. This valuable tool from CEVEC will assist us in offering clients a fully optimized human expression system that will express proteins with superior yields and in a shorter time frame than traditional methods. We look forward to a long relationship with CEVEC."

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Completion of a “First in Human” Clinical Phase I Study Using CAP® Cells
Consortium reported safe completion of clinical study with recombinant human Alkaline Phosphatase (hRESCAP®).
Tuesday, November 05, 2013
CEVEC and VPM Sign Exclusive License Agreement
Agreement on the clinical development of a novel human CMV vaccine.
Friday, January 04, 2013
CEVEC Signs License Agreement with Yuhan of South Korea
License will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems.
Friday, December 21, 2012
CEVEC Raises €6M to Grow CAP® Technology Based Protein and Vaccine Business
CEVEC announces closing of €6M financing round.
Tuesday, August 09, 2011
Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Zika Vaccines Prevent Disorders in Newborn Mice
Disorder immunity transmitted from female mice to pups following vaccination with two Zika vaccines.
Antibody Drug Conjugates May Help Personalize Radiotherapy
Biomarker-driven study shows promise in sensitizing HER2 positive tumors to radiation and chemotherapy.
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos